Tubidy MP3 & MP4

En popüler MP3 müziklerinizi ve MP4 videolarınızı ücretsiz indirin. Geniş bir multimedya içeriği seçkisini keşfedin ve sorunsuz indirmelerin tadını çıkarın.

High Throughput Screening of Affimer Proteins using SPRi Label-Free Technology

45:32 |

Yükleniyor...

İlgili Videolar

High Throughput Screening of Affimer Proteins using SPRi Label-Free Technology

45:32 |

How can affimer reagents provide novel solutions for drug discovery?

1:56 |

Combining High Throughput Screening with Image-Based Phenotyping advances drug discovery

26:05 |

Inhibitors of NSD2 Discovered by High-Throughput Screening with a Nucleosome Substrate

52:47 |

Accelerate Your Antibody Discovery with High Throughput Kinetic Screening of Phage Libraries

56:50 |

Selecting the right resin to achieve optimal results, from high throughput batch

53:26 |

Investigating Avidity and Neutralizing Ability of SARS-CoV-2 Patient Samples Using Next Gen BLI

36:45 |

Avacta Plc 'making significant progress towards commercialising Affimer platform'

6:21 |

Q&A with Avacta CEO, Alastair Smith

38:40 |

Peptidoteques Combinatòries (Phage Display)

43:02 |

Avacta Group heading into 'crucial year' for its cancer therapeutics programmes

4:47 |

Turner Pope Investor Evening - Avacta Group Presentation - 04th December 2017

23:55 |

Tubidy MP3 & MP4

High Throughput Screening of Affimer Proteins using SPRi Label-Free Technology

Type

Size

İlgili Videolar

High Throughput Screening of Affimer Proteins using SPRi Label-Free Technology

How can affimer reagents provide novel solutions for drug discovery?

Combining High Throughput Screening with Image-Based Phenotyping advances drug discovery

Inhibitors of NSD2 Discovered by High-Throughput Screening with a Nucleosome Substrate

Accelerate Your Antibody Discovery with High Throughput Kinetic Screening of Phage Libraries

Selecting the right resin to achieve optimal results, from high throughput batch

Avacta (AVCT) presentation at ShareSoc London 13th March 2019

Bitesize briefing – Avacta

Ultra-fast development of an anti-COVID-19 antibody

Avacta Group boss talks through 'excellent' Affimer study results

Alastair Smith, CEO of Avacta (AVCT)

Investigating Avidity and Neutralizing Ability of SARS-CoV-2 Patient Samples Using Next Gen BLI

Avacta Plc 'making significant progress towards commercialising Affimer platform'

Q&A with Avacta CEO, Alastair Smith

Peptidoteques Combinatòries (Phage Display)

Avacta Group heading into 'crucial year' for its cancer therapeutics programmes

Turner Pope Investor Evening - Avacta Group Presentation - 04th December 2017